"Ki-67 Antigen" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A CELL CYCLE and tumor growth marker which can be readily detected using IMMUNOCYTOCHEMISTRY methods. Ki-67 is a nuclear antigen present only in the nuclei of cycling cells.
| Descriptor ID |
D019394
|
| MeSH Number(s) |
D12.776.660.625.500 D23.050.290.500 D23.101.140.400
|
| Concept/Terms |
Ki-67 Antigen- Ki-67 Antigen
- Antigen, Ki-67
- Ki 67 Antigen
- Antigen Ki-67
- Antigen Ki 67
- Ki-67, Antigen
- MIB-1 Antigen
- Antigen, MIB-1
- MIB 1 Antigen
- MIB-1 Protein
- MIB 1 Protein
- Antigen Ki67
- Ki67, Antigen
|
Below are MeSH descriptors whose meaning is more general than "Ki-67 Antigen".
Below are MeSH descriptors whose meaning is more specific than "Ki-67 Antigen".
This graph shows the total number of publications written about "Ki-67 Antigen" by people in this website by year, and whether "Ki-67 Antigen" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 1 | 1 | 2 |
| 1997 | 0 | 1 | 1 |
| 1998 | 1 | 0 | 1 |
| 2000 | 0 | 5 | 5 |
| 2001 | 0 | 2 | 2 |
| 2003 | 0 | 1 | 1 |
| 2004 | 0 | 3 | 3 |
| 2005 | 0 | 6 | 6 |
| 2006 | 0 | 1 | 1 |
| 2007 | 0 | 4 | 4 |
| 2008 | 1 | 4 | 5 |
| 2009 | 1 | 2 | 3 |
| 2010 | 0 | 4 | 4 |
| 2011 | 0 | 2 | 2 |
| 2012 | 0 | 2 | 2 |
| 2013 | 0 | 1 | 1 |
| 2014 | 0 | 3 | 3 |
| 2015 | 0 | 1 | 1 |
| 2017 | 1 | 2 | 3 |
| 2018 | 0 | 2 | 2 |
| 2020 | 0 | 1 | 1 |
| 2021 | 0 | 2 | 2 |
| 2022 | 0 | 5 | 5 |
| 2023 | 0 | 2 | 2 |
| 2024 | 0 | 2 | 2 |
| 2025 | 1 | 0 | 1 |
| 2026 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Ki-67 Antigen" by people in Profiles.
-
Failure of human rhombic lip differentiation underlies medulloblastoma formation. Nature. 2022 09; 609(7929):1021-1028.
-
NF-?B Blockade by NEMO Binding Domain Peptide Ameliorates Inflammation and Neurobehavioral Sequelae After Cranial Radiation Therapy in Juvenile Mice. Int J Radiat Oncol Biol Phys. 2021 04 01; 109(5):1508-1520.
-
Primary and secondary gliosarcomas: clinical, molecular and survival characteristics. J Neurooncol. 2015 Nov; 125(2):401-10.
-
Low-grade small round cell tumor of the cauda equina with EWSR1-WT1 fusion and indolent clinical course. Hum Pathol. 2015 Jan; 46(1):153-8.
-
Survivin as a therapeutic target in Sonic hedgehog-driven medulloblastoma. Oncogene. 2015 Jul; 34(29):3770-9.
-
Recurrent ESR1-CCDC170 rearrangements in an aggressive subset of oestrogen receptor-positive breast cancers. Nat Commun. 2014 Aug 07; 5:4577.
-
A phase I-II study of the histone deacetylase inhibitor vorinostat plus sequential weekly paclitaxel and doxorubicin-cyclophosphamide in locally advanced breast cancer. Breast Cancer Res Treat. 2014 Jul; 146(1):145-52.
-
Emerging association between androgen deprivation therapy and male meningioma: significant expression of luteinizing hormone-releasing hormone receptor in male meningioma. Prostate Cancer Prostatic Dis. 2013 Dec; 16(4):387-90.
-
Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013 Oct; 24 Suppl 6:vi7-23.
-
Cytarabine, Ki-67, and SOX11 in patients with mantle cell lymphoma receiving rituximab-containing autologous stem cell transplantation during first remission. Cancer. 2013 Sep 15; 119(18):3318-25.